Anvisa confirms attendance at Cannabis Connection 2026
Anvisa confirms its attendance at Cannabis Connection 2026, which will address new rules, cultivation, the market, and regulatory impacts for companies and investors.
The Brazilian Health Regulatory Agency (Anvisa) has confirmed its presence at Cannabis Connection 2026, scheduled for November 5 in São Paulo. For companies, investors, and entrepreneurs in the sector, the agency's participation comes at an especially relevant moment: the Brazilian market has entered a phase in which regulatory changes are beginning to directly impact investment decisions, infrastructure, portfolios, and business models.
Hosted by Sechat, the gathering will center around the theme “The New Cannabis Landscape in Brazil” and will bring together government officials, researchers, companies, and experts to discuss agriculture, regulation, access, and market intelligence.
More than simply keeping up with new regulations, companies now need to understand how they will be implemented, what technical requirements must be integrated into operations, and where opportunities may arise along the supply chain.
From regulation to execution
In 2026, Brazilian regulation advanced across structural points of the chain. RDCs 1,012 and 1,013 established rules regarding research and cannabis cultivation by previously authorized legal entities.
Anvisa also published guidelines aimed at companies and institutions interested in obtaining a Special Authorization for cultivation. The document addresses aspects such as project drafting, facility adaptation, sanitary inspection, security, traceability, and plant control.
For those considering entering this market, these requirements have a direct impact on financial planning. Cultivation projects, for instance, no longer depend solely on genetics, agricultural productivity, and scale. They now require investments tied to sanitary compliance, security, traceability, quality control, and regulatory framework.
This also shifts the feasibility analysis for companies aiming to operate as technology suppliers, laboratories, service providers, agricultural operators, or pharmaceutical industry partners.
Three markets will be at the core of the discussion
The program for Cannabis Connection was structured to examine different parts of the Brazilian supply chain.
The first block will be dedicated to the agricultural market, including perspectives on cultivation, research, and the development of a domestic production chain.
Another focus will be RDC 1,015/2026, which concerns cannabis products regulated by Anvisa. The agenda will also cover RDC 660/2022, which governs the exceptional importation of products by patients for personal use.
For business leaders, this distinction is vital because all three segments present distinct regulatory and economic structures.
A company interested in domestic cultivation faces different requirements than one intending to register or commercialize products through the Anvisa-regulated channel. Likewise, the individual import market under RDC 660 features its own dynamics regarding procurement, distribution, prescription, and relationships with patients and healthcare professionals.
Understanding how these channels may evolve is essential for making decisions regarding market entry, capital allocation, partnership formation, and competitive positioning.
Anvisa's presence elevates regulatory debate
The Agency's confirmation reinforces the regulatory weight of the 2026 edition.
For the market, one of the primary challenges at this stage is translating the new rules into operational planning. There are still crucial decisions concerning the development of the domestic chain, the integration between cultivation and manufacturing, research, raw material supply, and corporate compliance with sanitary requirements.
Therefore, keeping track of how regulations are interpreted and enforced can be just as vital as understanding the text of the RDCs themselves.
For investors, the regulatory environment also directly shapes risk perception. Greater predictability around licensing, oversight, production, and commercialization enables companies to build investment projections and financial models with more solid assumptions.
Market data is also on the agenda
Cannabis Connection will also feature Fernanda Rebelo Carnevalli, a pharmacist and biochemist specializing in market intelligence and Market Insights at Close-Up International. Her work focuses on analyzing demand, medical prescriptions, distribution channels, and pharmaceutical market trends.
Also confirmed are Beatriz Marti Emygdio, researcher at Embrapa and president of the Permanent Strategic Advisory Committee on Cannabis, and Bruno Pegoraro, co-founder and president of Instituto Ficus.
The combination of regulation, agricultural research, and market intelligence aims to provide a broader perspective for companies deciding where to invest, which segments to monitor, and which regulatory shifts could impact their business over the coming years.
Sechat Guide 2026 to be launched during the event
The event will also mark the launch of the Sechat Cannabis Guide 2026, a publication that compiles regulatory information, market data, trends, and perspectives on cannabis across Brazil and Latin America.
The launch comes at a pivotal moment of reorganization for the Brazilian supply chain, shaped by new rules for cultivation, research, products, and prescriptions.
Event details
The 4th Cannabis Connection will take place on November 5, 2026, starting at 2:00 PM, at Edifício JK 1600, located at Avenida Presidente Juscelino Kubitschek, 1600, Itaim Bibi, São Paulo. The schedule includes market presentations, panel discussions, the launch of the Sechat Cannabis Guide, and a closing cocktail reception.
Spots are limited.